Figure 2
Major toxicities observed during the CARL trial and related published trials. The major levels of toxicity for different treatment schedules using a combination of PLD and vinorelbine are given as percentage of patients and as number of patients/total patients in trial. Grading according to CTCAEv3-criteria is given in Roman numerals. Black bars: study of Martin et al. (n = 34), vinorelbine 30 mg/m2 and PLD 35 mg/m2 every 4 weeks [20]; red bars: study of Burstein et al. (n = 21), vinorelbine 2 × 25-30 mg/m2 and PLD 40-50 mg/m2 every 4 weeks [19]; blue bars: CARL-Trial (n = 12), vinorelbine 2 × 25 mg/m2 and PLD 40 mg/m2 + plasmapheresis every 3 weeks. Unfortunately, the frequency of neutropenia < grade IV is not reported in the study of Martin et al.. PPE = palmar-plantar erythrodysesthesia, PLD: pegylated liposomal doxorubicin.